Immunotherapy "Shock" with Vitiligo Due to Nivolumab Administration As Third Line Therapy in Lung Adenocarcinoma

Overview

Journal Respir Med Case Rep

Date 2017 Nov 11

PMID 29124007

Citations 15

Authors

Paul Zarogoulidis

Haidong Huang

Theodora Tsiouda

Chrysa Sardeli

Georgia Trakada

Lemonia Veletza

Anastasios Kallianos

Christoforos Kosmidis

Aggeliki Rapti

Liana Papaemmanouil

Dimitrios Hatzibougias

Dimitrios Drougas

Chong Bai

Wolfgang Hohenforst-Schmidt

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.

Citing Articles

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.

Pasqualoni M, Orlandi A, Palazzo A, Garufi G, Cannizzaro M, Pontolillo L Front Oncol. 2023; 13:1067264.

PMID: 36969030 PMC: 10034067. DOI: 10.3389/fonc.2023.1067264.

Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.

Rao H, Guo Z, Wen X, Zeng X, Wu L, Huang L Front Oncol. 2023; 12:1099108.

PMID: 36713515 PMC: 9881409. DOI: 10.3389/fonc.2022.1099108.

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.

Dousset L, Pacaud A, Barnetche T, Kostine M, Dutriaux C, Pham-Ledard A JAAD Int. 2021; 5:112-120.

PMID: 34712997 PMC: 8529074. DOI: 10.1016/j.jdin.2021.09.002.

Lung cancer, treatment and nutritional status.

Pilikidou M, Palyvou F, Papadopoulou S, Tsiouda T, Tsekitsidi E, Arvaniti K Mol Clin Oncol. 2021; 15(6):248.

PMID: 34671467 PMC: 8521381. DOI: 10.3892/mco.2021.2410.

Targeting the PD-1/PD-L1 Axis in Human Vitiligo.

Willemsen M, Melief C, Bekkenk M, Luiten R Front Immunol. 2020; 11:579022.

PMID: 33240267 PMC: 7677560. DOI: 10.3389/fimmu.2020.579022.

References

Dugay F, Llamas-Gutierrez F, Gournay M, Medane S, Mazet F, Chiforeanu D . Clinicopathological characteristics of and rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget. 2017; 8(32):53336-53351. PMC: 5581114. DOI: 10.18632/oncotarget.18408. View

Planchard D, Smit E, Groen H, Mazieres J, Besse B, Helland A . Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017; 18(10):1307-1316. DOI: 10.1016/S1470-2045(17)30679-4. View

Zarogoulidis P, Rapti A, Sardeli C, Chinelis P, Athanasiadou A, Paraskevaidou K . Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series. Respir Med Case Rep. 2017; 21:171-175. PMC: 5458763. DOI: 10.1016/j.rmcr.2017.05.013. View

Zarogoulidis P, Chinelis P, Athanasiadou A, Porpodis K, Kallianos A, Rapti A . "Liquid elbows" due to afatinib administration. Respir Med Case Rep. 2017; 22:64-66. PMC: 5491760. DOI: 10.1016/j.rmcr.2017.06.013. View

Zarogoulidis P, Athanasiou E, Tsiouda T, Hatzibougias D, Huang H, Bai C . Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment. Respir Med Case Rep. 2017; 22:197-202. PMC: 5576975. DOI: 10.1016/j.rmcr.2017.08.017. View

Hu L, Mi W, Wu G, Wang Y, Mao-Ying Q . Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Curr Neuropharmacol. 2017; 17(2):184-196. PMC: 6343206. DOI: 10.2174/1570159X15666170915143217. View

Teulings H, Limpens J, Jansen S, Zwinderman A, Reitsma J, Spuls P . Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015; 33(7):773-81. DOI: 10.1200/JCO.2014.57.4756. View

De Pas T, Pala L, Catania C, Conforti F . Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. Future Oncol. 2017; 13(29):2629-2644. DOI: 10.2217/fon-2017-0262. View

Hahn A, Gill D, Agarwal N, Maughan B . PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 2017; 35(12):701-707. DOI: 10.1016/j.urolonc.2017.08.005. View

10.

Kimura K, Takayanagi R, Fukushima T, Yamada Y . Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment. Med Oncol. 2017; 34(10):178. DOI: 10.1007/s12032-017-1036-9. View

11.

Zarogoulidis P, Chinelis P, Athanasiadou A, Tsiouda T, Trakada G, Kallianos A . Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. Respir Med Case Rep. 2017; 22:101-105. PMC: 5519224. DOI: 10.1016/j.rmcr.2017.07.004. View

12.

Zarogoulidis P, Huang H, Bai C, Kosmidis C, Trakada G, Veletza L . Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series. Respir Med Case Rep. 2017; 22:187-196. PMC: 5576978. DOI: 10.1016/j.rmcr.2017.08.016. View

13.

Dai X, Guo G, Zou P, Cui R, Chen W, Chen X . (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017; 36(1):120. PMC: 5590185. DOI: 10.1186/s13046-017-0584-3. View

14.

Zarogoulidis P, Gaga M, Huang H, Darwiche K, Rapti A, Hohenforst-Schmidt W . Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?. Clin Transl Med. 2017; 6(1):6. PMC: 5243233. DOI: 10.1186/s40169-017-0135-8. View

15.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

16.

Sheng Z, Zhu X, Sun Y, Zhang Y . The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget. 2017; 8(34):57826-57835. PMC: 5593686. DOI: 10.18632/oncotarget.18406. View

17.

Domvri K, Darwiche K, Zarogoulidis P, Zarogoulidis K . Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl Lung Cancer Res. 2015; 2(4):256-8. PMC: 4367615. DOI: 10.3978/j.issn.2218-6751.2012.12.06. View

18.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffina M, DAveni A . Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl). 2017; 8:109-125. PMC: 5571822. DOI: 10.2147/LCTT.S119644. View

19.

Domvri K, Zarogoulidis P, Darwiche K, Browning R, Li Q, Turner J . Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer. 2013; 4(9):736-54. PMC: 3842443. DOI: 10.7150/jca.7734. View

20.

Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K . Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013; 5 Suppl 4:S389-96. PMC: 3791496. DOI: 10.3978/j.issn.2072-1439.2013.07.10. View